Ardelyx Bets Big On Tenapanor’s Potential, Despite Side Effect Concerns
This article was originally published in The Pink Sheet Daily
Unwinding NHE3 partnership with AstraZeneca, Ardelyx plans to move first-in-class agent into Phase III in IBS-C while seeking more tolerable dosing regimen for late-stage development in hyperphosphatasia.
You may also be interested in...
Tenapanor approved for IBS-C as Ibsrela, but Ardelyx is still seeking a commercial partner for that indication – and is maintaining focus on same molecule in hyperphosphatemia.
Ardelyx touts tenapanor's novel mechanism, favorable safety profile; advisory committee announcement reveals US Worldmeds’ bid to revive Novartis’ withdrawn Zelnorm.
Vaxxas thinks its vaccine-enhancement technology platform, Nanopatch, can bring in milestones and royalties just like a biotech drug candidate by offering increased potency and easier administration to makers of vaccines.